Blog

Hope Restored – Patients REGAIN Movement!

Breakthrough electrical stimulation therapy helps patients with spinal muscular atrophy regain lost motor function, with some able to walk farther than they have in years.

At a Glance

A clinical trial has shown that spinal cord electrical stimulation can restore motor function in spinal muscular atrophy (SMA) patients
The minimally invasive therapy improves muscle strength, walking ability, and reduces fatigue in SMA patients
Three participants underwent stimulation for 29 days, with all showing increased walking endurance by at least 20 meters
The approach could potentially treat other neurodegenerative diseases like ALS and Huntington’s disease
The therapy complements existing treatments that slow disease progression by actually reversing nerve cell dysfunction

Understanding Spinal Muscular Atrophy

Spinal Muscular Atrophy (SMA) is a genetic disorder that causes progressive motor neuron loss, leading to muscle weakness and significant movement impairments. The condition results from a mutation in the survival motor neuron 1 (SMN1) gene, which leads to insufficient production of a protein essential for motor neuron survival. As these specialized nerve cells deteriorate, patients experience progressive muscle weakness that can affect walking, breathing, swallowing, and other basic functions. Until recently, treatment options have primarily focused on slowing disease progression rather than reversing existing nerve damage.

Current standard treatments for SMA include nusinersen (Spinraza), risdiplam (Evrysdi), and onasemnogene abeparvovec (Zolgensma), which all aim to increase SMN protein production. While these medications have shown benefit in slowing disease progression, they do not address the existing motor neuron dysfunction or reverse established damage. This limitation highlights the need for complementary approaches that can improve function in already compromised neural circuits—a gap that electrical stimulation therapy may help fill.

The Breakthrough Study

Researchers at the University of Pittsburgh and Columbia University conducted a small pilot trial with three SMA patients to test whether electrical stimulation of the spinal cord could improve motor function. The participants underwent a 29-day treatment protocol, receiving spinal cord stimulation five times a week for two hours daily. The therapy involved placing electrodes in the lower back, specifically targeting sensory nerve roots that connect to motor neurons controlling leg muscles.

The researchers hypothesized that by stimulating sensory inputs to motor neurons, they could essentially “reawaken” nerve cells that had become dormant but were not yet dead. This approach differs significantly from traditional SMA treatments, which focus on preventing further degeneration rather than restoring function in existing circuits. The therapy is drug-free and minimally invasive, requiring only a small incision to place the electrodes that deliver carefully calibrated electrical impulses to the spinal cord.

Remarkable Results

The results of the trial were striking. All three participants showed improved motor function, increased walking endurance by at least 20 meters, reduced fatigue, and enhanced performance in daily activities. One participant showed particularly dramatic improvement, becoming able to walk from his temporary housing to the research lab—something impossible before the treatment. The stimulation appeared to increase motoneuron firing rates and reverse maladaptive changes that had occurred in these cells due to the disease.

What makes these findings particularly significant is that improvements continued throughout the treatment period, suggesting that longer periods of stimulation might yield even greater benefits. The results were consistent across all participants, regardless of their disease progression stage or whether they were simultaneously receiving SMN-inducing therapies. This consistency indicates that the approach might be broadly applicable to various SMA patients at different stages of the disease.

Future Implications

The success of this pilot study has significant implications that extend beyond SMA. The approach demonstrates that targeted electrical stimulation can alleviate motor deficits by reversing maladaptive processes in spinal circuits, a principle that could potentially apply to other neurodegenerative diseases affecting motor function. The research team is now planning larger clinical trials to assess the long-term effectiveness and safety of electrical spinal cord stimulation for SMA patients.

The study, published in Nature Medicine, represents the first demonstration that neurotechnology can reverse neural circuit degeneration in a human neurodegenerative disease. Rather than competing with existing SMA treatments, this approach complements them by addressing a different aspect of the disease process. While medications like nusinersen and risdiplam help prevent further deterioration by increasing SMN protein production, electrical stimulation helps restore function in surviving but dysfunctional motor neurons, potentially offering a more comprehensive treatment strategy for SMA patients.